Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
N-Acetyl Semax Amidate
N-Acetyl Semax, a synthetic peptide, has gained recognition for its remarkable neurogenic and neurorestorative qualities.
Dosing & scaling, explained
No mass-based amount example with adequate calculation context is available for this compound. This is educational source context, not a protocol or recommendation.
No source-supported amount ladder is shown
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for N-Acetyl Semax Amidate
What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical, 3 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical4 rows | |||||
| Russian label, Semax 0.1% nasal drops, vascular cognitive problems (parent)Adults with cognitive and memory impairment from vascular brain lesions, dyscirculatory encephalopathy or transient ischemic attacks | 200-2000 mcg per administration (3-30 mcg/kg); 800-8000 mcg per day (7-70 mcg/kg) | 2-3 drops into each nostril 4 times a day | Intranasal drops (0.1% solution, 1 drop holds 50 mcg) | 10-14 daysCourse repeated if needed; no fixed interval stated | Community resource2026 |
| The manufacturer's instruction states that 60-70% of the dose is absorbed from the nasal mucosa and that no more than 2-3 drops should go into each nostril at once, with 10-15 minute gaps if a larger dose is needed. The same label gives separate schedules for head injury, neurosurgery and anesthesia (1400-3500 mcg three times a day for 3-5 days), mental fatigue prevention (400-900 mcg a day for 3-5 days) and optic nerve disease (600-900 mcg a day for 7-10 days). | |||||
| Russian label, Semax 1% nasal drops, acute ischemic stroke (parent)Adults in the acute phase of ischemic stroke | Moderate stroke: 2000-3000 mcg per administration, 6000-12,000 mcg per day. Severe stroke: 3000-4000 mcg per administration, 12,000-20,000 mcg per day | 3-4 times a day at 3-4 hour intervals (moderate); 4-5 times a day at 2.5-3 hour intervals (severe) | Intranasal drops (1% solution, 1 drop of 0.05 mL holds 500 mcg) | 10 daysNone described | Community resource2026 |
| The 1% label works in milligrams rather than micrograms: 2-3 drops per nostril per administration for moderate strokes and 3-4 drops per nostril for severe ones. It reports no identified cases of overdose and describes the peptide as practically non-toxic on single and prolonged administration. | |||||
| Acute hemispheric stroke study that set the labelled doses (parent)30 patients in the acute phase of hemispheric ischemic stroke, against 80 conventionally treated controls | 12 mg per day (moderate strokes) or 18 mg per day (severe strokes) | Daily, divided through the day | Intranasal | 5 days (moderate) or 10 days (severe)None described | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)1997 |
| Adding Semax to intensive care sped the regression of general cerebral and focal deficits, especially motor ones, assessed with clinical rating scales, EEG mapping and somatosensory evoked potentials. It is a 1997 Russian-language study with a non-randomized control group, and these are the figures the 1% label reproduces. | |||||
| Post-stroke rehabilitation with two courses (parent)110 adults after ischemic stroke, in early (about 89 days) or late (about 214 days) rehabilitation, with and without Semax | 6000 mcg per day | Daily | Intranasal | Two 10-day courses20 days between the two courses | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2018 |
| Plasma BDNF rose and stayed elevated in the Semax groups regardless of when rehabilitation started, and Barthel index recovery was faster with better final scores. The study was open-label with subgroup comparisons rather than placebo control, and its 6 mg daily dose sits between the two label strengths. | |||||
| Preclinical3 rows | |||||
| Rat hippocampal BDNF and TrkB study (parent)Rats tested on conditioned avoidance learning | 50 mcg/kg body weight | Single application | Intranasal | Single doseNot applicable | Brain Research (PubMed)2006 |
| One dose produced a 1.4-fold rise in hippocampal BDNF protein, a 1.6-fold rise in TrkB phosphorylation and 3-fold and 2-fold rises in BDNF exon III and TrkB mRNA, alongside more conditioned avoidance reactions. This is the mechanistic study most often cited for the whole Semax family, and it used the parent peptide in rats. | |||||
| Rodent monoamine study (parent)Rats and mice, striatal microdialysis and locomotor testing | 0.15 mg/kg | Single dose | Intraperitoneal | Single doseNot applicable | Neurochemical Research (PubMed)2005 |
| Striatal 5-HIAA tissue content rose about 25% at 2 hours and extracellular 5-HIAA rose to 180% over 1-4 hours, while Semax alone did not change dopamine levels but sharply amplified the dopamine release and locomotion produced by amphetamine. The dopaminergic story in community guides rests on this amplification effect rather than on a direct dopamine rise. | |||||
| Rat stroke transcriptome study (parent)Rats after transient middle cerebral artery occlusion | 10 mcg per 100 g of body weight (100 mcg/kg) per injection | Three doses, at 90 minutes, 2.5 hours and 6.5 hours after the occlusion | Intraperitoneal | Single day, with brain tissue sampled at 24 hoursNot applicable | Genes (PubMed)2020 |
| RNA sequencing found 394 genes differentially expressed versus saline at 24 hours, with Semax suppressing inflammation genes and raising neurotransmission genes, the opposite of what ischemia-reperfusion alone did. The authors frame this as compensation of disrupted expression patterns rather than a single receptor mechanism. | |||||
| Community-reported3 rows | |||||
| Once-daily nasal course for the analog | 300 mcg (1 spray) to 600 mcg (2 sprays) | Once daily in the morning | Intranasal metered spray, reconstituted at about 2 mg/mL (5 mg vial in 2.5 mL) | 2-4 weeks1-2 weeks off between cycles | Community resource2026 |
| This June 2026 guide treats once-daily dosing as the analog's selling point, claiming an 8-12 hour window against 4-6 hours for the parent, and keeps dosing to mornings because the longer tail can delay sleep. Those duration figures are presented as reported rather than measured, and the page states the analog is not a registered medicine anywhere. | |||||
| Tiered nasal and injection practice for the analog | 100-150 mcg to start; 300-600 mcg per day nasally; 100-300 mcg per day if injected | Once daily, or 300 mcg morning plus 300 mcg early afternoon at the top of the range | Nasal drops or spray; subcutaneous injection also described (10 mg in 2 mL gives 5 mg/mL, so 300 mcg is 6 units) | 10-14 days, or 2-4 weeks for nootropic useEqual time off, 10-14 days or 2-4 weeks | Community resource2026 |
| A September 2026 profile sets the community microgram tier beside the Russian clinical doses of 12 and 18 mg a day and labels the analog row as vendor practice with no trial validation. It states that no half-life has been measured for the capped peptide and that the often-quoted 30-40 minute figure is a vendor extrapolation. | |||||
| Research-chemical spray and injection chart for the analog | 600-900 mcg per day nasally (2-3 pumps of 300 mcg); 500 mcg rising to 1000 mcg per day if injected | 2-3 times daily (nasal) or once to twice daily (injected) | Intranasal spray at 0.1% or 0.3%, each pump delivering 300 mcg; or subcutaneous injection | Up to 30 days at 900 mcg a day, or up to 60 days at 600 mcg a dayWashout equal to the length of the course | Community resource2024 |
| This chart advises waiting 60 seconds between sprays into the same nostril and switching nostrils between doses. Its figures are vendor practice rather than trial data, and the page notes that the Russian stroke protocols it references used far larger daily amounts over 10 days. | |||||
How a course is commonly described
- First doseCommunity-reported
Community guides describe onset 30-60 minutes after a nasal dose with a peak at 2-4 hours, and claim a total 8-12 hour window for the capped form against 4-6 hours for the parent. No pharmacokinetic study of the analog has been published, so these are practitioner impressions.
- Days 1-14Community-reported
The common pattern is 300 mcg once each morning, moving to 600 mcg split between morning and early afternoon, with nothing in the evening because the peptide is activating. Guides describe a steadier baseline of focus over the first one to two weeks rather than a single acute effect.
- BreakCommunity-reported
Every community schedule inserts an off period: equal time off after a 10-14 day course, or 1-2 weeks after a 2-4 week run, justified as resetting responsiveness. The Russian labels similarly describe courses of 10-14 days rather than continuous use.
- Repeat courses, clinical patternClinical
The clearest published repeat schedule is from post-stroke rehabilitation: two 10-day courses of 6000 mcg a day separated by 20 days, with plasma BDNF staying elevated across the study. That is roughly ten times the daily amount community guides describe, given for a different purpose.
- Clinical comparisonClinical
Registered Russian use is short and dose-heavy: 800-8000 mcg a day of the 0.1% drops for 10-14 days for vascular cognitive problems, or 6-20 mg a day of the 1% drops for 10 days in acute stroke. Nothing in either label resembles the open-ended daily nootropic use described online.
- PubChem lists the acetylated amidated peptide as its own compound, but no published study has tested it. The human and animal evidence above is all for plain Semax, and the claim that the caps roughly double its duration is chemistry reasoning rather than a measured half-life.
- Registered Semax dosing is far larger than community dosing and much shorter: micrograms per kilogram four times a day for 10-14 days, or 6-20 mg a day for 10 days in stroke. The 300-600 mcg daily nootropic tier has no trial behind it in either form.
- Semax is a prescription medicine only in Russia; neither it nor the capped analog is approved by the FDA or EMA, and the analog is sold strictly as a research chemical. The rows above record what sources report, not endorsements of use.
Sources for this section (10)
- Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)
- The efficacy of semax in the treatment of patients at different stages of ischemic stroke
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus
- Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents
- Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats
Plus 5 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
N-Acetyl Semax Amidate is a capped version of Semax, the seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) built from the 4-10 fragment of adrenocorticotropic hormone with a Pro-Gly-Pro tail, developed at Moscow State University and the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax carries no hormonal activity and is registered in Russia as nasal drops in two strengths: 0.1% as a nootropic for vascular cognitive problems, head injury and optic nerve disease, and 1% for acute ischemic stroke. The acetyl and amide groups on the analog are meant to block the aminopeptidase and carboxypeptidase routes that clear the parent quickly, but no published study has measured the capped peptide's pharmacokinetics or effects, so its profile is inferred from Semax. The analog is not a registered medicine anywhere and is sold only as a research chemical.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Research on N-Acetyl Semax Amidate
Brain function enhancement and cognitive health applications
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Research on N-Acetyl Semax Amidate
Brain function enhancement and cognitive health applications
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2
Also listed as
N-acetyl semax amidate, N-acetyl semax, NA-Semax amidate, HY-P3588, EX-A13574
InChIKey
QQOAKFVAEDCKGY-HPMAGDRPSA-N
IUPAC name
(4S)-4-[[(2S)-2-acetamido-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[2-[(2S)-2-carbamoylpyrrolidin-1-yl]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.